{
  "id": 3057571,
  "title": "Safety concerns spur FDA to again halt testing of Regenxbio gene therapy",
  "url": "https://urgent.news/2026/08/24/safety-concerns-spur-fda-to-again-halt-testing-of-regenxbio-gene",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-24T15:55:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/regenxbio-fda-hunter-syndrome-hold-mri-safety/828578/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns",
        "url": "https://urgent.news/2026/08/24/stat-fda-pauses-regenxbio-gene-therapy-trial-again-due-to-safety",
        "published": "2026-08-24T11:59:48.000Z"
      },
      {
        "outlet": "Endpoints News",
        "title": "Regenxbio hit with another clinical hold for Hunter syndrome gene therapy",
        "url": "https://urgent.news/2026/08/24/regenxbio-hit-with-another-clinical-hold-for-hunter-syndrome-gene",
        "published": "2026-08-24T15:17:56.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}